Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Efficacy and Safety of Tildrakizumab in Elderly Patients With Psoriasis: A Narrative Review.","authors":"Alice B Gottlieb, Joseph F Merola","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Tildrakizumab is an anti-interleukin 23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. Globally, patients aged ≥65 years are 9.8% to 12.8% of patients with psoriasis who are treated with biologics, but they are often underrepresented in clinical trials.</p><p><strong>Objective: </strong>To summarize the available evidence on the efficacy and safety of tildrakizumab in patients aged ≥65 years with psoriasis for a United States (US)-based healthcare practitioners audience.</p><p><strong>Methods: </strong>A PubMed search was conducted using the search terms \"(tildrakizumab OR MK-3222 OR Ilumya) AND psoriasis AND (elderly OR 65 years)\" to identify English-language clinical trials and real-world studies evaluating efficacy and safety of tildrakizumab in elderly patients with psoriasis.</p><p><strong>Results: </strong>Two clinical trials and 5 real-world studies describing the efficacy and safety of tildrakizumab in patients aged ≥65 years were identified. The short- and long-term efficacy of tildrakizumab was comparable between patients aged <65 and ≥65 years. Adverse events were consistent with those observed among the overall clinical trial population, with some expected increases in age-related events.</p><p><strong>Limitations: </strong>The number of studies with data for patients aged ≥65 years, and sample sizes within some studies, were small, limiting interpretation.</p><p><strong>Conclusion: </strong>Based on available data, the established efficacy and safety profiles of tildrakizumab are maintained in patients aged ≥65 years with moderate-to-severe plaque psoriasis. Practical considerations, including insurance coverage, quarterly maintenance dosing, and in-office administration, in the US may increase treatment adherence and make tildrakizumab an appropriate treatment option for elderly patients.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 5","pages":"35-42"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148457726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective Effects of an Advanced Antioxidant Serum and an Encapsulated Vitamin C Serum From UV-Induced Erythema and Oxidative Stress.","authors":"Saeid Amini-Nik, Robert M Law, Vinay Bhardwaj, Stephen Lynch, Diane B Nelson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the protective effects of 2 antioxidant products against UV light by assessing UV-induced erythema and skin damage biomarkers.</p><p><strong>Methods: </strong>A randomized, controlled trial enrolled 15 healthy women aged 35 to 60 years. Participants' lower backs were marked with 4 test sites (5 cm × 6 cm). Test products (4 mg/cm²) were applied daily for 4 days. Untreated/irradiated and naïve sites served as controls. After determining each participant's minimal erythema dose (MED), skin was exposed to UV irradiation at 1× and 2× MED. Erythema, imaging, and skin damage were evaluated. Analysis of markers was determined from biopsies using histochemical imaging and scoring by a dermatopathologist (2× MED site).</p><p><strong>Results: </strong>Pretreatment with the advanced antioxidant serum (TAP) demonstrated 72% (1× MED, <i>P</i>=0.02) and 300% less erythema (2× MED, <i>P</i><0.001) vs an encapsulated vitamin C serum (Encap-C) and 75% (1× MED, <i>P</i>=0.01) and 354% (2× MED, <i>P</i><0.001) vs control. Pretreatment with TAP demonstrated significant protective effects vs Encap-C and control at 1× and 2× MED for matrix metalloproteinase 9 (<i>P</i>=0.004 and <i>P</i>=0.005, respectively), thymine dimers (both <i>P</i><0.001), sunburn cell count (<i>P</i>=0.008 and <i>P</i><0.001, respectively), p53 (<i>P</i><0.001, both), CD68 (<i>P</i>=0.001 and <i>P</i><0.001, respectively), and total lymphocyte count (both <i>P</i><0.001). Encap-C did not demonstrate significant differences in erythema or biomarker levels vs control.</p><p><strong>Limitations: </strong>This study was conducted in healthy participants (mean age: 49 years), with limited representation across Fitzpatrick skin types. Future studies should include a more diverse study population.</p><p><strong>Conclusion: </strong>Pretreatment with TAP demonstrated significantly less UV-induced erythema and provided significantly greater cellular protection vs Encap-C serum and untreated/irradiated skin.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 5","pages":"9-16"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148457744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of Long-Standing Irritable Bowel Syndrome Symptoms After Treatment of Psoriasis With Risankizumab.","authors":"Jose Gaspar de Alba, Marley Cutrona, Ahuva Cices, Diego Ruiz Dasilva, Graham H Litchman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Psoriasis is a chronic immune-mediated inflammatory disease associated with systemic comorbidities, including gastrointestinal disorders. Emerging evidence supports a bidirectional gut-skin axis, with shared immunologic pathways involving the interleukin (IL)-23/IL-17 axis. Irritable bowel syndrome (IBS), traditionally considered a functional disorder, has also been linked to low-grade inflammation and cytokine dysregulation. We report a case of a 67-year-old man with moderate plaque and inverse psoriasis and longstanding IBS with diarrhea (IBS-D) who experienced complete resolution of gastrointestinal symptoms following treatment with risankizumab, an IL-23 inhibitor. Improvement in IBS symptoms began within weeks of therapy initiation and was sustained at follow-up, alongside complete skin clearance. No other changes in medications or lifestyle were identified. This case highlights a potential role of IL-23-mediated inflammation in IBS pathophysiology and suggests that targeted inhibition of the IL-23/IL-17 axis may benefit select patients with concurrent dermatologic and gastrointestinal disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 5","pages":"54-56"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148457885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hispanic and Latino Ethnicity and Acculturation: Influences on Skin Cancer Prevention Attitudes and Behaviors.","authors":"Luis F Andrade, Maria J Lalama, Parsa Abdi, Yasmine Nousari, Gizelle Godinez, Lea Tordjman, Denisse Montana, Carmen Nicole Beliz, Shasa Hu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hispanic and Latino (H/L) populations are among the fastest-growing minority groups in the United States (US), projected to collectively reach 27.5% of the population by 2060. Despite a lower melanoma incidence compared to non-Hispanic White (NHW) individuals, H/L individuals face disproportionately higher disease burdens, including later-stage diagnoses and worse prognoses. While differences in sun-protective behaviors and UV exposure have been noted between H/L and NHW populations, the role of acculturation-a process by which individuals adopt the cultural norms of a dominant society-remains underexplored in dermatologic health. A cross-sectional survey study was conducted from August 2023 to August 2024 of adult patients capable of providing informed consent and fluent in English or Spanish. The survey included 32 questions covering sociodemographic data, the validated Short Acculturation Scale for Hispanics, and items adapted from prior sun protection behavior studies. A total of 257 responses were collected; 160 respondents (62%) self-identified as H/L, and 141 (55%) were born outside the United States. H/L participants were more likely than non-H/L respondents to avoid peak sun exposure hours (<i>P</i>=0.003) and to wear hats (<i>P</i>=0.03). Among H/L respondents, higher acculturation scores were significantly associated with increased use of sunglasses (<i>P</i><0.001) and daily water intake (<i>P</i>=0.002). However, overall acculturation did not influence 83.3% of surveyed health behaviors. Socioeconomic status was a stronger predictor of sun-protective practices; H/L participants from lower socioeconomic backgrounds were less likely to perform or be aware of self-skin examinations (<i>P</i>=0.01) and less likely to wear sunglasses (<i>P</i>=0.08). H/L individuals were approximately 20% less likely than non-H/L participants to perform regular self-skin exams (relative risk: 0.81; 95% confidence interval: 0.62-1.05). Contrary to prior assumptions, acculturation to US culture showed limited influence on most sun-protective behaviors among H/L adults in this study. Instead, socioeconomic disparities and occupational exposure-particularly in high UV-risk industries such as agriculture and construction-may contribute more directly to increased melanoma burden in this population. These findings underscore the need for dermatologic public health strategies that consider socioeconomic and occupational risk factors alongside cultural dynamics. Future multicenter studies are recommended to further explore these relationships and to improve skin cancer prevention efforts in H/L communities.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Surgical Tray Setup and Instrument Selection in Dermatologic Surgery.","authors":"Roger I Ceilley, Shandhan Sureshbabu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A well-organized surgical tray and deliberate instrument selection are essential components of high-quality dermatologic surgery. Proper setup enhances workflow efficiency, minimizes errors, and supports patient safety. Moreover, growing attention to cost and sustainability highlights the importance of reducing instrument waste without compromising the quality of care. This article reviews best practices for tray preparation, discusses historical and modern perspectives on instrument selection, and provides practical recommendations for improving efficiency in dermatologic surgery.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"18-19"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Treatment of Perioral (Periorificial) Dermatitis With Topical Roflumilast 0.3% Cream: An Illustrative Case Study With Rapid Onset and Prolonged Remission.","authors":"Erik Domingues","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Periorificial dermatitis is a common inflammatory dermatosis most often presenting in adult women around the mouth with a distinctive sparing of the vermilion border. Involvement may also cluster around the eyes and nose. Steroid use is most commonly implicated in this condition. Treatments include topical and oral antibiotics, sulfur-based creams and cleansers, azelaic acid, and nonsteroidal anti-inflammatory agents. Roflumilast cream, 0.3%, was approved in 2022 for the treatment of chronic plaque psoriasis, including intertriginous areas. Here, we present the case of a 30-year-old female patient who presented with periorificial dermatitis, which cleared in 5 days with once daily roflumilast cream, 0.3%, without adverse events, tolerability concerns, or recurrence 11 months after treatment initiation.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"26-27"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Therapeutic Potential of Topical Honey in Atopic Dermatitis.","authors":"Aileen Park, Lanah Almatroud, Leo Wan, Peter Lio","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"7-9"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Analysis of Thyrotropin Levels in Patients With Nonscarring Alopecia: A Single-Center Retrospective Comparative Study.","authors":"Simona A Alomary, Nicole J Baker, Nicholas Schell, Temitayo Ogunleye, Susan Taylor, Heather Milbar","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To compare thyrotropin (TSH) levels across nonscarring alopecia (NSA) subtypes-alopecia areata (AA), telogen effluvium (TE), and androgenetic alopecia (AGA)-in a primary analysis of all patients, a secondary analysis of euthyroid patients stratified into low-normal (0.5-2.5 mIU/L) and high-normal (2.5-4.5 mIU/L) categories, and a tertiary analysis of patients with thyroid dysfunction.</p><p><strong>Methods: </strong>A retrospective chart review was conducted on patients diagnosed with AA, TE, or AGA at a single academic dermatology department between August 2017 and August 2024. TSH values were drawn within 3 months of the initial visit, and patient demographics were extracted from the electronic medical record. Patients with thyroid dysfunction were excluded from the secondary analysis. TSH values within the euthyroid range were stratified into low-normal and high-normal categories. A tertiary analysis of patients with frank thyroid dysfunction was later conducted. Descriptive statistics, Kruskal-Wallis tests, and Bonferroni-corrected pairwise comparisons were performed.</p><p><strong>Results: </strong>Among the 1,411 patients initially identified, most TSH values were within the euthyroid range. In a secondary analysis of 1,291 euthyroid patients, there was no significant difference in TSH distribution across NSA subtypes, including when stratified into low-normal vs high-normal categories. Among patients with thyroid dysfunction (8.5%), those with TE had the highest relative proportions of both hypothyroidism (5.0%) and hyperthyroidism (5.5%). Black or African American patients with AA and TE had lower mean TSH levels than White patients; however, this was not observed in AGA.</p><p><strong>Limitations: </strong>Limitations of this study include the retrospective design and the potential for incomplete or biased medical records.</p><p><strong>Conclusion: </strong>TSH levels among patients with NSA did not vary significantly based on NSA subtype. Racial differences in mean TSH were observed in AA and TE, but the clinical significance remains uncertain.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"35-37"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pipeline of Devices and Aesthetics: What Is Left?","authors":"Albert Zhou, Timothy Klufas, Erik Choi, Todd Schlesinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Aesthetic dermatology is experiencing a continued shift toward minimally invasive procedures with the least amount of patient downtime. Herein we focus on the advancements and evolving technologies in the development for neurotoxins, fillers, exosomes, microneedling, and microcoring devices that are currently available or in development. These treatment advancements offer dermatologists a broader range of tools, enabling more patients to pursue cosmetic treatments with greater comfort and individualized care.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"30-34"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Isotretinoin: An Option for the Treatment of Scalp and Facial Rosacea.","authors":"Madeline Lillich, Mikel Muse, Izabelle Bermudez, Sabiha Uddin, James Appel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extrafacial rosacea involving the scalp is an uncommon manifestation of acne rosacea, for which evidence-based treatment guidance is limited. With this retrospective study, we aimed to evaluate the effectiveness and tolerability of low-dose isotretinoin in patients with rosacea involving both the face and scalp. We conducted an observational chart review of adult male patients treated with isotretinoin for this condition at our multisite private practice between 2012 and 2022; 21 patients met inclusion criteria. Treatment courses were short with a low dose (mean cumulative dose: 81.0 mg/kg; mean daily dose: 0.67 mg/kg/day; mean duration: 3.95 months). Complete clinical clearance of facial and scalp disease was achieved in 85.7% of patients, and treatment was well tolerated, with 95.2% of patients completing a full therapeutic course. This study suggests that low-dose, short-duration isotretinoin is a viable and effective systemic treatment option for extrafacial rosacea and may fill an important gap in the management of refractory scalp disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 4","pages":"28-29"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}